Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | 177Lu-PSMA-617 vs. cabazitaxel for mCRPC

Michael Hofman • 20 May 2020
ASCO 2020
Prostate Cancer

Michael Hofman, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses a randomised phase II trial (NCT03392428) of investigating a 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Michael Hofman

1:26
[68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in metastatic ccRCC
Michael Hofman • 25 Jan 2024
1:20
Advances in theranostics for prostate cancer
Michael Hofman • 25 Jan 2024
2:01
The emerging role of PET tracers in managing renal cell carcinoma
Michael Hofman • 25 Jan 2024
5:37
177Lu-PSMA-617 for the early treatment of prostate cancer
Michael Hofman • 16 Feb 2021

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals